Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (5971)	10/13/1998 7:13:00 PM
From: hilm	Read Replies (1) \| Respond to of 9523

Another take... Viagra Maker's Profits Soar By PHIL GALEWITZ AP Business Writer NEW YORK (AP) _ Despite slowing sales of its impotence-treatment drug Viagra, Pfizer Inc. (PFE - news) more than doubled its profits in the third quarter, the company said Tuesday. Pfizer earned $1.40 billion, or $1.06 a diluted share, in the third quarter ended Sept. 27, up 134 percent from $596 million, or 46 cents a share, in the same period last year. Pfizer's sales rose 21 percent to $3.3 billion. Results came in below analysts' expectations, however, partly because it had a lower tax rate a year ago. In advance of the report, which was released after the close of trading on the New York Stock Exchange, Pfizer tumbled $5.50 to close at $87.50 a share. Sales of Viagra, the fastest-selling new drug ever when it was launched in April, were $141 million in the third quarter. That was down sharply from the $411 million in the second quarter. Year-to-date Viagra sales totaled $551 million. So far more than 5 million prescriptions have been written for 3 million patients. The company said it was not surprised that sales have slowed from its record initial pace. Pfizer said its remained comfortable with analysts earnings estimates of $2.05 a share to $2.10 a share from its continuing operations in 1998. In the third quarter, earnings from continuing operations rose 15 percent to $667 million, or 51 cents a diluted share. It expects fourth-quarter profits to be bolstered by an increase in Viagra sales as a result of an advertising program. For the first nine months of the year, profits rose 64 percent to $2.72 billion, or $2.06 a diluted share, from $1.66 billion, or $1.27 a share, a year earlier. Revenue rose 21 percent to reach $9.6 billion. William C. Steere, Jr., chairman and chief executive officer, said Pfizer's outlook is bright because patents on its current product line are protected well into the next century and that the company has an impressive mix of products under development.